Bio-Rad Laboratories, Inc. (BIO): Price and Financial Metrics


Bio-Rad Laboratories, Inc. (BIO)

Today's Latest Price: $581.71 USD

2.67 (0.46%)

Updated Oct 23 7:00pm

Add BIO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

BIO Stock Summary

  • BIO has a market capitalization of $16,602,973,886 -- more than approximately 89.2% of US stocks.
  • BIO's went public 34.83 years ago, making it older than 92.9% of listed US stocks we're tracking.
  • Price to trailing twelve month operating cash flow for BIO is currently 40.06, higher than 90.93% of US stocks with positive operating cash flow.
  • Stocks that are quantitatively similar to BIO, based on their financial statements, market capitalization, and price volatility, are FTV, CERN, RDY, TFX, and XYL.
  • Visit BIO's SEC page to see the company's official filings. To visit the company's web site, go to www.bio-rad.com.

BIO Stock Price Chart Interactive Chart >

Price chart for BIO

BIO Price/Volume Stats

Current price $581.71 52-week high $586.20
Prev. close $579.04 52-week low $309.38
Day low $574.03 Volume 99,642
Day high $586.20 Avg. volume 224,708
50-day MA $523.59 Dividend yield N/A
200-day MA $450.74 Market Cap 17.26B

Bio-Rad Laboratories, Inc. (BIO) Company Bio


Bio-Rad Laboratories manufactures and supplies products and systems used to separate complex chemical and biological materials, as well as to identify, analyze, and purify their components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics. The company was founded in 1952 and is based in Hercules, California.

BIO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$581.71$163.08 -71%

Below please find a table outlining a discounted cash flow forecast for BIO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Bio-Rad Laboratories Inc ranked in the 20th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for BIO, they are:

  • The company's debt burden, as measured by earnings divided by interest payments, is 109.99; that's higher than 96.74% of US stocks in the Healthcare sector that have positive free cash flow.
  • The business' balance sheet reveals debt to be 4% of the company's capital (with equity being the remaining amount). Approximately merely 12.58% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • BIO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 46.2% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-71%
1%-71%
2%-71%
3%-71%
4%-70%
5%-70%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as BIO, try NRC, ABT, AZN, BAX, and GMED.


BIO Latest News Stream


Event/Time News Detail
Loading, please wait...

BIO Latest Social Stream


Loading social stream, please wait...

View Full BIO Social Stream

Latest BIO News From Around the Web

Below are the latest news stories about Bio-Rad Laboratories Inc that investors may wish to consider to help them evaluate BIO as an investment opportunity.

Antinuclear Antibody Test Market (COVID - 19 Updates) 2020 to See Stunning Growth Worldwide, Leading Players -Alere Inc., Bio-Rad Laboratories, ERBA Diagnostics, Trinity Biotech, Thermo Fisher Scientific, Inc., Antibodies Incorporated

DBMR has added a new report titled Anti-Nuclear Antibody Test Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The data and the information regarding the industry are taken

OpenPR | October 1, 2020

Immunohistochemistry Market To Witness Steady Growth With Danaher, Merck KGaA, Thermo Fisher Scientific, PerkinElmer, Abcam Plc, Agilent Technologies, Bio SB, Bio-Rad Laboratories, Cell Signalling Technology and F. Hoffmann-La Roche among others

A report by The Insight Partner's on the Immunohistochemistry Market discusses the growth of the market in great detail. It discusses thoroughly all factors promoting and deterring the market. The report also focuses on the competitive dynamics in the market

OpenPR | October 1, 2020

Apoptosis Assays Market Sees a Faster Rebound in the Era of COVID-19 | Industry Size, Share, Growth Factors, Development Strategy, Top Leaders-Thermo Fisher Scientific, Inc., BD, Bio-Rad Laboratories, Promega, Abcam plc, Research And Diagnostic Systems, I

DBMR has added a new report titled Apoptosis Assays Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The data and the information regarding the industry are taken from consistent

OpenPR | September 30, 2020

Gel Permeation Chromatography Market: COVID-19 Business Continuity Plan | Evolving Opportunities with Agilent Technologies Inc. and Bio-Rad Laboratories Inc. | Technavio

LONDON--(BUSINESS WIRE)-- #GelPermeationChromatographyMarket--The Global Gel Permeation Chromatography Market will grow by $381.67 mn during 2020-2024

Business Wire | September 30, 2020

Gene Expression Market Reflect a Holistic Expansion With Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., PerkinElmer, Bio-Rad Laboratories, OriGene Technologies, Illumina, Inc., QIAGEN

A report by The Insight Partner's on the Gene Expression Market discusses the growth of the market in great detail. It discusses thoroughly all factors promoting and deterring the market. The report also focuses on the competitive dynamics in the

OpenPR | September 29, 2020

Read More 'BIO' Stories Here

BIO Price Returns

1-mo 17.71%
3-mo 12.79%
6-mo 31.14%
1-year 68.28%
3-year 161.77%
5-year 312.94%
YTD 57.21%
2019 59.34%
2018 -2.70%
2017 30.94%
2016 31.46%
2015 15.01%

Continue Researching BIO

Want to see what other sources are saying about Bio-Rad Laboratories Inc's financials and stock price? Try the links below:

Bio-Rad Laboratories Inc (BIO) Stock Price | Nasdaq
Bio-Rad Laboratories Inc (BIO) Stock Quote, History and News - Yahoo Finance
Bio-Rad Laboratories Inc (BIO) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8153 seconds.